Programmed Death-ligand 1 Positron Emission Tomography Imaging During Neoadjuvant (Chemo)radiothErapy in Esophageal and Rectal Cancer (PETNEC): a Prospective Non-randomized Open-label Single-center Pilot Study

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test, Radiation
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The overall aim of this pilot study is to prospectively monitor programmed death-ligand 1 (PD-L1) expression dynamics in vivo, during neoadjuvant chemoradiotherapy (CRT) or short-course preoperative radiotherapy (SCPRT) in rectal and esophageal cancer by a positron emission tomography (PET) imaging approach.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:

• 18 years of age and older

• All sexes

• Histologically confirmed carcinoma of the rectum or oesophagus (squamous cell carcinoma and adenocarcinoma, including oesophago-gastric junction cancers)

• Medical need for a neoadjuvant CRT/SCPRT

• Suitable to withstand the course of neoadjuvant CRT/SCPRT

• Written informed consent form (ICF) for participation in the study

Locations
Other Locations
Austria
Medical University of Vienna
RECRUITING
Vienna
Contact Information
Primary
Johannes Laengle, MD, PhD
johannes.laengle@meduniwien.ac.at
+43140400 69260
Backup
Michael Bergmann, MD
michael.bergmann@meduniwien.ac.at
+43140400 69260
Time Frame
Start Date: 2022-11-01
Estimated Completion Date: 2026-06-01
Participants
Target number of participants: 20
Treatments
Other: Neoadjuvant Chemoradiotherapy (CRT)
Other: Short-course preoperative radiotherapy (SCPRT)
Other: Neoadjuvant Chemoradiotherapy (CROSS protocol)
Related Therapeutic Areas
Sponsors
Leads: Johannes Laengle, MD, PhD

This content was sourced from clinicaltrials.gov